<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226056</url>
  </required_header>
  <id_info>
    <org_study_id>S075SORD01</org_study_id>
    <nct_id>NCT01226056</nct_id>
  </id_info>
  <brief_title>Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets</brief_title>
  <official_title>Phase I/II Trial With Sorafenib in Combination With RAD001 Administered Orally in Patients With Advanced Solid Tumors, Selected on the Base of Molecular Targets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Europe New Drug Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern Europe New Drug Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sorafenib is an oral multikinase inhibitor and among its targets are several RTKs involved in&#xD;
      tumor genesis (Raf, Flt-3, c-Kit and RET) and angiogenesis (VEGFR1, 2 and 3 and PDGFRß).&#xD;
      Therefore sorafenib inhibits tumor growth by a dual mechanism, acting either directly on the&#xD;
      tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through&#xD;
      inhibition of VEGFR and PDGFR signaling.&#xD;
&#xD;
      RAD001 is a novel derivative of rapamycin. It selectively inhibits mTOR directly blocking&#xD;
      tumor cells by preventing tumor cell growth and proliferation and indirectly by inhibiting&#xD;
      angiogenesis (via potent inhibition of the HIF-1 and consequently VEGF production).&#xD;
&#xD;
      Targeting mTOR in combination with sorafenib might lead to more profound effects on tumor&#xD;
      cell biology than could be achieved through individual targeting of some proteins.&#xD;
&#xD;
      New drugs have often met only limited success since not always target pathways responsible&#xD;
      for tumor development and growth are targeted. To overcome this problem, the specific&#xD;
      pathways targeted by the investigators two drugs will be analyzed in each single patient&#xD;
      before the inclusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    toxicity (protocol amendment under approval)&#xD;
  </why_stopped>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Maximum Tolerated Dose (MTD)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The maximum tolerated dose (MTD) is defined as the dose in which 2 of 3 or 2 of 6 patients experience a DLT. The Recommended Dose is identified as one dose level below the MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: PFS (Progression Free survival) rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Pharmacokinetics profile of both drugs</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: overall survival</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>every 8 weeks</time_frame>
    <description>Evaluated according to RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs</measure>
    <time_frame>36 months</time_frame>
    <description>graded according to CTCAE criteria v3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RAD001 in combination with sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001 in combination with sorafenib</intervention_name>
    <description>Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.&#xD;
The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).&#xD;
Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.</description>
    <arm_group_label>RAD001 in combination with sorafenib</arm_group_label>
    <other_name>RAD001 (Everolimus)</other_name>
    <other_name>Sorafenib (Nexavar®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with progressive disease of advanced solid tumours judged non suitable for&#xD;
             standard treatment&#xD;
&#xD;
          2. Biopsiable lesion or archive tissue not older than 1 year to assess the expression of:&#xD;
&#xD;
               -  phosphorylated AKT&#xD;
&#xD;
               -  phosphorylated p70S6&#xD;
&#xD;
               -  RKIP (Raf Kinase Inhibitor Protein)&#xD;
&#xD;
               -  phosphorylated ERK1/2 The presence of at least one of the previous targets will&#xD;
                  be mandatory for patient enrolment&#xD;
&#xD;
          3. At least 1 uni-dimensional measurable lesion according to modified RECIST&#xD;
&#xD;
          4. Life expectancy of at least 12 weeks&#xD;
&#xD;
          5. Age ≥ 18 years old&#xD;
&#xD;
          6. ECOG Performance Status of 0 or 1&#xD;
&#xD;
          7. Adequate bone marrow, liver, and renal function as assessed by the following&#xD;
             laboratory requirements to be conducted within 7 days prior to start of first dose:&#xD;
&#xD;
               -  Haemoglobin ≥9.0 g/dL (5.6 mmol/L)&#xD;
&#xD;
               -  Absolute neutrophil count (ANC)≥1.5 x 109/L&#xD;
&#xD;
               -  Platelet count ≥100 x 109/L&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT and AST ≤2.5 x ULN (≤5 x ULN for patients with liver involvement of their&#xD;
                  cancer)&#xD;
&#xD;
               -  Alkaline phosphatase ≤4 x ULN&#xD;
&#xD;
               -  PT-INR/PTT &lt;1.5 x ULN&#xD;
&#xD;
               -  Serum albumin levels ≥2.5 mg/dl&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x ULN&#xD;
&#xD;
          8. HBV/HCV testing in the 2 weeks before treatment start in specific categories of&#xD;
             patient with hepatitis B and C risk factors and in additional patients at the&#xD;
             discretion of the investigators according to guidelines in Appendix 6.&#xD;
&#xD;
          9. All fertile patients must use adequate contraception while on study and for three&#xD;
             subsequent months&#xD;
&#xD;
         10. Ability to understand and the willingness to sign a written informed consent. A signed&#xD;
             informed consent must be obtained prior to performing any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiac disease: congestive heart failure (NYHA II-IV), active coronary&#xD;
             artery disease - CAD (MI more than 6 months prior to study entry is allowed), cardiac&#xD;
             arrhythmias requiring antiarrhythmic therapy (betablockers or digoxin are permitted)&#xD;
             or uncontrolled hypertension&#xD;
&#xD;
          2. History of HIV infection or chronic hepatitis B or C&#xD;
&#xD;
          3. Patients with NSCLC squamous histotype&#xD;
&#xD;
          4. Recurrent hemoptysis or cerebrovascular accident within 12 months, or peripheral&#xD;
             vascular disease with claudication on less than 1 block (about 150 metres), or history&#xD;
             of clinically significant bleeding non-traumatic&#xD;
&#xD;
          5. Deep venous thrombosis or pulmonary embolus within 1 year or ongoing need for&#xD;
             full-dose oral or parenteral anticoagulation&#xD;
&#xD;
          6. Clinically active infections (&gt; Grade 2 NCI-CTC AE version 3.0)&#xD;
&#xD;
          7. Evidence of CNS tumor metastases&#xD;
&#xD;
          8. History of organ allograft&#xD;
&#xD;
          9. Pre-existing thyroid abnormality where thyroid function cannot be maintained in the&#xD;
             normal range by medication&#xD;
&#xD;
         10. Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
         11. Second malignancies within the past 5 years (except for non - melanoma skin cancer and&#xD;
             cervical carcinoma in situ)&#xD;
&#xD;
         12. Pregnant or breast-feeding patients&#xD;
&#xD;
         13. Substance abuse, medical, psychological, or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
         14. Any condition that is unstable or could jeopardize the safety of the patient and&#xD;
             his/her compliance in the study&#xD;
&#xD;
         15. Patients unable to swallow oral medications&#xD;
&#xD;
         16. Any malabsorption condition&#xD;
&#xD;
         17. Prior treatment with sorafenib or m-TOR inhibitors&#xD;
&#xD;
         18. Ongoing requirement for systemic corticosteroid medication or other immunosuppressants&#xD;
&#xD;
         19. Radiotherapy within 3 weeks of start of study drug. Palliative radiotherapy is&#xD;
             allowed. Major surgery within 4 weeks of study entry&#xD;
&#xD;
         20. Radiotherapy involving &gt; 30% of the active bone marrow&#xD;
&#xD;
         21. Autologous bone marrow transplant or stem cell rescue within 4 months of study entry&#xD;
&#xD;
         22. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry.&#xD;
             Patients taking chronic erythropoietin are permitted provided no dose adjustment is&#xD;
             undertaken within 2 months prior to the study or planned during the study period&#xD;
&#xD;
         23. Investigational drug therapy outside of this trial during or within 4 weeks of study&#xD;
             entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>filippo De Braud, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IEO, Milano (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia,</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>October 20, 2010</last_update_submitted>
  <last_update_submitted_qc>October 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Scientific Director</name_title>
    <organization>SENDO</organization>
  </responsible_party>
  <keyword>advanced solid tumors</keyword>
  <keyword>Sorafenib (Nexavar®)</keyword>
  <keyword>RAD001 (everolimus)</keyword>
  <keyword>tumor molecular targets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

